The Pharma Letter16h
Merck's Keytruda and Citius' Lymphir combo trial shows promising results
Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...
Business Insider21h
Medicenna announces single-agent activity of MDNA11 from dose expansion cohort
Repeat administration of MDNA11 at the target doses continues ... Cohort 3: 120 microgram/kg Q2W MDNA11 and 400 mg Q6W KEYTRUDA; Cohort 4: 120 microgram/kg Q3W MDNA11 and 400 mg Q6W KEYTRUDA.
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...
Merus: Petosemtamab Set Up For December 2024 Data Presentation
Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...